Haemonetics Co. to Post FY2025 Earnings of $4.56 Per Share, Zacks Research Forecasts (NYSE:HAE)

Haemonetics Co. (NYSE:HAE - Free Report) - Equities research analysts at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for Haemonetics in a note issued to investors on Thursday, September 12th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings per share of $4.56 for the year, up from their previous forecast of $4.55. The consensus estimate for Haemonetics' current full-year earnings is $4.58 per share. Zacks Research also issued estimates for Haemonetics' Q4 2025 earnings at $1.22 EPS, Q3 2026 earnings at $1.23 EPS, Q4 2026 earnings at $1.41 EPS and FY2026 earnings at $5.11 EPS.

Other research analysts have also issued research reports about the company. Bank of America assumed coverage on Haemonetics in a research report on Wednesday. They set a "neutral" rating and a $85.00 price objective for the company. JMP Securities reissued a "market outperform" rating and set a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 13th. Citigroup dropped their price objective on shares of Haemonetics from $94.00 to $85.00 and set a "neutral" rating on the stock in a report on Thursday, August 22nd. BTIG Research began coverage on shares of Haemonetics in a research note on Tuesday. They set a "buy" rating and a $112.00 target price for the company. Finally, Needham & Company LLC upgraded shares of Haemonetics from a "hold" rating to a "buy" rating and set a $112.00 price target on the stock in a research note on Wednesday, June 12th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Haemonetics has an average rating of "Moderate Buy" and an average target price of $106.14.

Haemonetics Stock Performance

HAE stock traded up $2.83 during midday trading on Friday, reaching $76.09. The company had a trading volume of 670,477 shares, compared to its average volume of 535,663. The firm has a market capitalization of $3.89 billion, a PE ratio of 33.23, a P/E/G ratio of 1.32 and a beta of 0.30. The stock has a 50 day moving average price of $81.38 and a 200 day moving average price of $83.89. Haemonetics has a fifty-two week low of $70.74 and a fifty-two week high of $97.97. The company has a quick ratio of 2.33, a current ratio of 3.76 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The business had revenue of $336.17 million during the quarter, compared to the consensus estimate of $335.08 million. During the same quarter in the previous year, the business posted $1.05 earnings per share. The company's quarterly revenue was up 8.0% compared to the same quarter last year.

Insider Buying and Selling

In other news, EVP Anila Lingamneni sold 2,136 shares of Haemonetics stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total transaction of $192,240.00. Following the transaction, the executive vice president now directly owns 21,410 shares in the company, valued at approximately $1,926,900. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, EVP Anila Lingamneni sold 2,136 shares of the stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $90.00, for a total transaction of $192,240.00. Following the completion of the sale, the executive vice president now directly owns 21,410 shares of the company's stock, valued at $1,926,900. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Stewart W. Strong sold 4,312 shares of the firm's stock in a transaction on Friday, July 26th. The stock was sold at an average price of $91.15, for a total value of $393,038.80. Following the sale, the insider now directly owns 18,196 shares of the company's stock, valued at $1,658,565.40. The disclosure for this sale can be found here. 1.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Haemonetics

Several hedge funds have recently made changes to their positions in HAE. Commonwealth Equity Services LLC raised its stake in Haemonetics by 3.3% during the 2nd quarter. Commonwealth Equity Services LLC now owns 3,673 shares of the medical instruments supplier's stock valued at $304,000 after purchasing an additional 117 shares during the period. QRG Capital Management Inc. raised its position in Haemonetics by 6.9% during the second quarter. QRG Capital Management Inc. now owns 4,031 shares of the medical instruments supplier's stock valued at $333,000 after buying an additional 260 shares during the period. Arizona State Retirement System boosted its position in Haemonetics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 14,217 shares of the medical instruments supplier's stock worth $1,176,000 after acquiring an additional 272 shares during the period. State of Michigan Retirement System grew its stake in Haemonetics by 2.5% during the 1st quarter. State of Michigan Retirement System now owns 12,474 shares of the medical instruments supplier's stock valued at $1,065,000 after acquiring an additional 300 shares in the last quarter. Finally, Natixis Advisors L.P. increased its holdings in shares of Haemonetics by 2.1% in the 4th quarter. Natixis Advisors L.P. now owns 15,819 shares of the medical instruments supplier's stock valued at $1,352,000 after purchasing an additional 324 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.